Drug Discovery World

MAY 7, 2024

This means we are able to hijack the cell machinery to be even more efficient than before to produce more of what we want (mAb) and less of what we don’t want (impurities) through the different genetic editing tools for cell engineering. RA: How can anion exchange (AEX) chromatographic approaches improve production processes for antibodies?

Antibody 59

Antibody Production Manufacturing Engineer 59

Pharmaceutical Technology

SEPTEMBER 1, 2022

While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation. “For

Manufacturing 130

Manufacturing Bacterium Reagent Production 130

Roots Analysis

FEBRUARY 21, 2022

Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. The evolution of NGS technologies has made it possible to sequence thousands of genes with a suspected genetic disease predisposition, in a very short period of time and at minimal costs.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

JANUARY 10, 2023

Our catalog of over 6,500+ primary antibodies, 1,200+ secondary antibodies, and 50+ ELISA kits includes reagents for multiplex IF, flow cytometry, and more in fields including immunology, oncology, and neuroscience. Pillar 6: Genetic Strategies. Custom antibody development.

Antibody 52

Antibody Protein Reagent Scientist 52

The Pharma Data

JANUARY 31, 2021

It will offer chosen startups with access to investment and business guidance from Sequoia Capital China, and access to Illumina’s sequencing systems, reagents and genomics expertise. The new incubator will have two funding cycles per year, each six months long. All will be in a fully operational laboratory space in Shanghai, China.

Life Science 52

Life Science Genome Genomics Reagent 52

Drug Discovery World

SEPTEMBER 28, 2022

Winners will be evaluated based on criteria that include research objective, genomic reagent request, and how the product would be used in the field of research. . Grant program research areas include nucleic acid extraction, liquid biopsy, long-read sequencing, and genomics applications.

Genome 52

Genome Genomics Research Life Science 52

Drug Discovery World

JANUARY 30, 2024

Dr Naldini open new doors for cures for otherwise untreatable genetic diseases with the full impact of his work still untapped”, she said. High-cost materials: Specialised equipment, reagents, and cell culture media significantly contribute to the overall cost. Automating and scaling up manufacturing is crucial for cost reduction.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years.

Genotype 52

Genotype Reagent Genetics Research 52

Camargo

MAY 2, 2021

In chimeric antigen receptor T-cell (CAR-T) therapy, cells are genetically modified before being (re)introduced into the patient, representing the intersection between gene and cell therapy. Both have tremendously evolved in recent years. Identify critical development issues or deficiencies to address.

Gene Therapy 155

Gene Therapy Gene Packaging Packaging 155

FDA Law Blog

MAY 19, 2023

The submission will need to include a “detailed description of a protocol for continuous monitoring, identification, and handling of genetic mutations and/or novel isolates or strains.” Continuous Monitoring and Post Market Reporting Special Controls Within the Special Control for Risk Analysis are details regarding continuous monitoring.

Reagent 40

Reagent Genetics Contamination Marketing 40

The Pharma Data

MARCH 16, 2022

3, and Delta ([link] About TIB Molbiol TIB Molbiol is a subsidiary of Roche Diagnostics that has supplied the global market with reagents for research and medical diagnostics for over 30 years. These kits can detect and differentiate between Omicron subvariants BA.1,

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

OCTOBER 19, 2023

This could involve tweaking experimental conditions, changing reagents or redesigning the assay. There is also an increasing focus on personalized and precision medicine, where treatments are tailored to individual patients based on genetic or molecular data, which requires assays to detect and quantify these unique markers.

Scientist 59

Scientist Development Research Compliance 59

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. MELBOURNE, Australia, Jan. Quarterly Results Release Date and Webinar.

Genetics 52

Genetics Reagent Biobanking Production 52

pharmaphorum

FEBRUARY 3, 2021

“A recent report indicates that autologous T cells that carry multiple CRISPR-Cas9-mediated genetic modifications designed to improve persistence and efficacy can be safely administered to patients with refractory cancer, providing an important step forward in the use of CRISPR in immune cell therapies”.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

The Pharma Data

MARCH 13, 2021

HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system.

Drugs 52

Drugs Antibody Production Medicine 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

OCTOBER 27, 2020

.” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY ® System.

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

The Pharma Data

JULY 11, 2021

Hereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. About Hereditary Angioedema. The swelling can be debilitating and painful. 7,8 HAE affects an estimated 1 in 50,000 people worldwide.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Roots Analysis

OCTOBER 16, 2023

These genes possess the following characteristics: GC content: Moderate (40-65%) No critical hairpin loops Not more than 20 bp repeats Not more than 20bp hairpin stretches Complex Genes: The interaction of a gene with external factors, either environmental or genetic, influences the normal trait, making it complex.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

DECEMBER 15, 2022

Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced short palindromic repeat (CRISPR) nucleases have been heralded for their enormous potential to treat diseases and genetic disorders. Likewise, Lessard et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

APRIL 13, 2023

Anything you can do to reduce costs is good – and savings on reagents are clearly a key driver for labs to miniaturise. When you try to scale down the volumes used in these methods, you soon run into a host of challenges around certain reagent types, different liquid viscosities, and tricky tasks such as bead clean-ups.

Genome 52

Genome Genomics Reagent Development 52

Drug Discovery World

FEBRUARY 15, 2023

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Genetically engineered mouse models (GEMM) recapitulate the stromal biology of different human cancers including the tumour microenvironment that regulates the disease process.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

JULY 18, 2023

Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

MARCH 13, 2023

Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed. Genetic Engineering & Biotechnology News. In reality, the situation revealed that, before the pandemic, many in the industry failed to plan well. August 2020.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

JUNE 6, 2023

“We’re still seeing those at the meeting at the moment”, he said, and thinks they still hold great promise for patients the better we understand patient genetics. He said: “We saw patient transcriptomics from CRUK this week, particularly all the data coming out from the TRACERx study, looking at the evolution of lung cancer.

Protein 52

Protein DNA RNA Research 52

Drug Discovery World

FEBRUARY 8, 2023

The threat of empty capsids Capsids are the protein shell that would usually enclose the genetic material of a virus. Partially-filled capsids may also be present, and contain packaged process-related impurities or truncated genetic material. In AAV therapeutics, empty capsids are those that are not packaged with the therapeutic DNA.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

JUNE 14, 2023

Besides looking at donor characteristics, our platform, which we call Excellos 360TM, includes the assessment of metabolic and effector potential of cells, and genetic analysis.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

XTalks

OCTOBER 1, 2020

Sooter has also found success in industry, leading and bringing together the work of different teams of researchers at NeuBase to help drive the company’s goal of developing cures and treatments for genetic diseases, including Huntington’s Disease. She says, “It’s been a lot of fun; it’s a decision I’m glad I made.”.

Scientist 52

Scientist In-Vitro Research Life Science 52